	US 11,780,913 B2
	IL-1β neutralizing human monoclonal antibodies
Cheng-I Wang, Singapore (SG); Angeline Goh, Singapore (SG); Siok Ping Yeo, Singapore (SG); Alessandra Rosa Mortellaro, Singapore (SG); Subhra Kumar Biswas, Singapore (SG); Florent Ginhoux, Singapore (SG); and Pingyu Zhong, Singapore (SG)
Assigned to Agency for Science, Technology and Research, Singapore (SG)
Filed by Agency for Science, Technology and Research, Singapore (SG)
Filed on Oct. 1, 2020, as Appl. No. 17/61,194.
Application 16/192,537 is a division of application No. 14/378,442, granted, now 10,167,335, issued on Jan. 1, 2019, previously published as PCT/SG2013/000057, filed on Feb. 13, 2013.
Application 17/061,194 is a continuation of application No. 16/192,537, filed on Nov. 15, 2018, granted, now 10,919,962.
Claims priority of application No. 201201007-0 (SG), filed on Feb. 13, 2012.
Prior Publication US 2021/0024627 A1, Jan. 28, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); C07K 16/24 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/245 (2013.01) [A61K 39/3955 (2013.01); A61K 2039/505 (2013.01); C07K 2317/10 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)]

9 Claims

1. An isolated monoclonal antibody which specifically binds to IL-1, or an antigen binding fragment thereof, wherein said antibody or fragment thereof comprises:

(i) a light chain sequence comprising the amino acid sequence of SEQ ID NO: 17; and

(ii) a heavy chain sequence comprising the amino acid sequence of SEQ ID NO: 18 or SEQ ID NO: 2.